Allergic Inflammation
Allergic Inflammation - Related Videos
07:52
Analysis of Pulmonary Dendritic Cell Maturation and Migration during Allergic Airway Inflammation
0 Views •
Cited by 1 •
2012
We describe a strategy to monitor maturation and migration of pulmonary dendritic cells in response to ovalbumin in the setting of ovalbumin induced allergic airway inflammation. This strategy can be modified to assess migration of pulmonary dendritic cells in settings of infection.
02:06
Allergic Reactions
0 Views •
2019
Overview We speak of an allergy when the immune system triggers a response against a benign foreign structure, like food, pollen or pet dander. These elicitors are called allergens. If the immune system of a hypersensitive individual was primed against a specific allergen, it will trigger allergic symptoms during every subsequent encounter of the allergen. Symptoms can be mild, such as hay fever, to severe, such as potentially fatal anaphylactic shock. Sensitization Is the First Step of an...
01:38
Inflammation
0 Views •
2019
Overview In response to tissue injury and infection, mast cells initiate inflammation. Mast cells release chemicals that increase the permeability of adjacent blood capillaries and attract additional immune cells to the wound or site of infection. Neutrophils are phagocytic leukocytes that exit the bloodstream and engulf invading microbes. Blood clotting platelets seal the wound and fibers create a scaffold for wound healing. Macrophages engulf aging neutrophils to end the acute inflammatory...
01:27
Allergic Drug Reactions
0 Views •
2023
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...
01:30
Allergic Reactions: Anaphylaxis
0 Views •
2026
Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...
FAQs
IgE cross-linking functions as the signal that activates mast cells after a sensitized individual encounters the allergen again. This activation causes release of mediators such as histamine and leukotrienes, which then promote symptoms including itching, swelling, mucus production, and airway narrowing. Pharmacologically, this step connects allergen recognition with targets for symptom control and anti-inflammatory treatment.
Eosinophils help sustain allergic inflammation after the initial mediator release. Histamine and leukotrienes contribute to signals that recruit these cells into affected tissues, extending the inflammatory response beyond the immediate mast-cell reaction. Their involvement helps explain why allergic disorders can continue producing tissue swelling, mucus, or airway effects rather than resolving immediately after allergen exposure.
Different effects emerge from the actions of mediators released during the response. Histamine contributes to itching and swelling, while leukotrienes are associated with inflammatory signaling and airway narrowing. Together, these mediators can also promote mucus production. Linking each symptom to mediator activity helps pharmacologists evaluate which pathway a treatment should reduce.
These treatments act on different parts of the allergic inflammatory response. Antihistamines target histamine-related effects, corticosteroids reduce inflammatory signaling, and leukotriene modifiers act on leukotriene-associated pathways. This distinction allows pharmacological strategies to be matched to the mechanisms contributing to symptoms, while mechanistic studies help identify opportunities for more targeted and safer therapies.
Treatment development can follow the sequence from allergen-triggered IgE and mast-cell activation to mediator release, eosinophil recruitment, and persistent tissue inflammation. Therapies may therefore be evaluated according to whether they reduce mediator-driven symptoms or broader inflammatory signaling. This pathway-based approach gives pharmacologists a framework for studying how different drug classes influence allergic responses.
The pathway is relevant to asthma, allergic rhinitis, dermatitis, and other hypersensitivity disorders. In these conditions, investigators can examine how inflammatory signaling relates to clinical effects such as airway narrowing, mucus production, itching, or swelling. Studying the shared pathway supports evaluation of treatments that reduce symptoms or interrupt the signaling processes underlying tissue inflammation.
Mechanistic studies clarify how sensitization, IgE cross-linking, mast-cell mediator release, and eosinophil recruitment contribute to disease-related effects. This information supports testing of therapies directed at specific stages rather than treating symptoms without understanding their source. In pharmacology, such studies are important for developing safer, more targeted approaches to allergic and hypersensitivity disorders.